Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -6 of 6
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
11/14/2008
 
First Published:
11/20/2003
1.
Phase I/II Study of Vaccination With Autologous Monocyte-Derived Dendritic Cells Transfected With RNAs Encoding For Melan-A, MAGE-3, and Survivin Antigens in Patients With Stage IV Cutaneous Melanoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Active
18 and over
Other
ERLANGEN-DERMA-ER-DC-06
EU-20317, NCT00074230
Last Modified:
10/31/2008
 
First Published:
11/1/1999
2.
Phase II Study of Adoptive Transfer of Cloned Lymphocytes With Interleukin-2 After Cyclophosphamide and Fludarabine in Patients With Metastatic Melanoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
16 and over
NCI
NCI-99-C-0158
NCI-T99-0078, T99-0078, NCT00019942
Last Modified:
11/16/2008
 
First Published:
5/28/2004
3.
Phase II Study of Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody (MDX-010) and Peptide Vaccine Comprising Tyrosinase, gp100 Antigen, and MART-1 Antigen Emulsified in Montanide ISA-51 in Patients With Resected Stage III or IV Melanoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
NCI, Pharmaceutical / Industry
MCC-15241
MDX-010-16, NCI-6446, 6446, NCT00084656, LAC-USC-10M036
4.
Immunotherapy of Melanoma Patients
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Active
18 and over
Other
LUD 1998-009
NCT00112216
5.
Immunotherapy of Stage III/IV Melanoma Patients
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Active
18 and over
Other
LUD 2001-003
NCT00112242
6.
Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Active
Over 18
Other
Pro00000806
IND # BB-13545, NIH OBA # 0708-874, NCT00672542
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute